Company Statement: Sanofi divests Dermik Dermatology Unit to Valeant Pharmaceuticals International
MLex Summary: Sanofi, a pharmaceutical company specialising in healthcare has announced the divestiture of its dermatology unit, Dermik, to Valeant Pharmaceuticals in a deal worth 425 million dollars.The statement follows in...To view the full article, register now.
Already a subscriber? Click here to view full article